Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
19 Mayo 2024 - 11:15AM
Business Wire
Savara’s Partner, Trillium Health LLC,
Presented Data on the Laboratory Blood Test for Diagnosing aPAP
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage
biopharmaceutical company focused on rare respiratory diseases,
presented a poster at the American Thoracic Society (ATS) 2024
International Conference that is taking place May 17-22, 2024, in
San Diego, CA. Savara’s partner, Trillium Health LLC, presented a
poster on the laboratory blood test that was recently developed to
aid in the diagnosis of aPAP.
Below are summaries of the posters presented:
Poster Board 701: “Healthcare Burden of Pulmonary Alveolar
Proteinosis” presented by E. Lee, M.D., Ph.D.; sponsored by Savara
Inc.
- Presented data from a retrospective cohort analysis using a
longitudinal claims database (IPM.ai) comparing the clinical and
economic burden of a sample of 2,312 pulmonary alveolar proteinosis
(PAP) patients to 9,247 non-PAP matched controls.
- Data demonstrated PAP patients experience higher healthcare
resource utilization and higher pharmaceutical and
non-pharmaceutical costs as evidenced by a 4-fold increase in
hospital admissions, 6-fold increase in in-patient visits, and a
4-fold increase in cost of care, as well as higher rates of
comorbidities, procedures, and therapy use (all parameters
p<0.001), thereby highlighting a significant unmet need in this
rare disease patient population.
- Click here to view the abstract.
- Lee E, Ataya A, McCarthy C, Cosenza J, Bielecki S, Wang TS.
Healthcare burden of pulmonary alveolar proteinosis. Am J Respir
Crit Care Med 2024;209:A1173.
Poster Board 702: “Development of a Novel Laboratory Test for
the Detection of GM-CSF Antibodies to Aid in the Diagnosis of
Individuals At-risk for Autoimmune Pulmonary Alveolar Proteinosis
(aPAP)” presented by A. Ali and J. Kim of Trillium Health
LLC
- Presented data on the development and performance
characteristics of a novel laboratory test for the detection of
granulocyte-macrophage colony-stimulating factor (GM-CSF)
antibodies in human serum to aid in the diagnosis of aPAP.
- Clinical accuracy of 100% was achieved in a cohort of 40
subjects (negative cohort n=20, positive cohort n=20),
demonstrating Trillium’s particle-based flow cytometry immunoassay
test offers a highly precise and sensitive laboratory test for the
determination of GM-CSF antibody levels in human serum and, thus,
can successfully be used as a tool to definitively diagnose
aPAP.
- Click here to view the abstract.
- Kim J, Cornish D, Ali A. Development of a novel laboratory test
for the detection of GM-CSF antibodies to aid in the diagnosis of
individuals at-risk for autoimmune pulmonary alveolar proteinosis
(aPAP). Am J Respir Crit Care Med 2024;209:A1174.
The full content of these posters is available in the Articles
and Publications page of the Savara corporate website.
Additionally, the abstracts are published in a supplement of the
American Journal of Respiratory and Critical Care Medicine
(AJRCCM). For more details about the ATS International Conference
please visit https://conference.thoracic.org/index.php.
About aPAP
Autoimmune PAP is a rare lung disease characterized by the
abnormal build-up of surfactant sediment in the alveoli (or air
sacs) of the lungs. The surfactant consists of proteins and lipids
and is an important physiological substance that lines the inside
of the alveoli to prevent the lungs from collapsing. In a healthy
lung, the old and inactivated surfactant is cleared and digested by
immune cells called alveolar macrophages. Alveolar macrophages need
to be stimulated by granulocyte-macrophage colony-stimulating
factor (GM-CSF) to function properly in clearing surfactant, but in
autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF,
rendering the macrophages unable to perform their tasks. As a
result, an excess of surfactant accumulates in the alveoli, causing
obstruction of gas exchange, and patients start to experience
shortness of breath, often with cough and frequent fatigue.
Patients may also experience chronic cough, as well as episodes of
fever, chest pain, or coughing blood, especially if secondary lung
infection develops. In the long-term, the disease can lead to
serious complications, including lung fibrosis and the need for a
lung transplant.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim nebulizer
solution, is an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
Forward-Looking Statements
Savara cautions you that statements in this press release that
are not a description of historical fact are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements may be identified by
the use of words referencing future events or circumstances such as
“expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,”
among others. Savara may not actually achieve any of the matters
referred to in such forward-looking statements, and you should not
place undue reliance on these forward-looking statements. These
forward-looking statements are based upon Savara’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, the outcome of
our ongoing and planned clinical trials for our product candidate,
the ability to project future cash utilization and reserves needed
for contingent future liabilities and business operations, the
availability of sufficient resources for Savara’s operations and to
conduct or continue planned clinical development programs, the
ability to successfully develop our product candidate, the risks
associated with the process of developing, obtaining regulatory
approval for and commercializing drug candidates such as
molgramostim that are safe and effective for use as human
therapeutics, and the timing and ability of Savara to raise
additional capital as needed to fund continued operations. All
forward-looking statements are expressly qualified in their
entirety by these cautionary statements. For a detailed description
of our risks and uncertainties, you are encouraged to review our
documents filed with the SEC including our recent filings on Form
8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue
reliance on forward-looking statements, which speak only as of the
date on which they were made. Savara undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240519208921/en/
Savara Inc. IR & PR Anne Erickson
(anne.erickson@savarapharma.com) (512) 851-1366
Savara (NASDAQ:SVRA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Savara (NASDAQ:SVRA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024